Home LiteratureArticle Details
PMID: 9258818 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma.

Journal of neuro-oncology ·Vol. 34 ·No. 3 ·1997-09-00 ·Pages 263-78

Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu MA, Yung WK, Brada M, Newlands E

Abstract

The purpose of the study was to assess health-related quality of life (HQL) in patients with high-grade malignant glioma of the brain. The EORTC core Quality of Life Questionnaire (QLQ-C30) and a Brain Cancer Module (BCM20) were administered at baseline and several weeks later (follow-up) to 105 patients with either recently-diagnosed (n = 41) or recurrent (n = 64) malignant glioma. In addition, the attending neurologists completed a standard neurological examination, a modified Barthel Activities of Daily Living Index (BADLI) and the Karnofsky Performance Scale (KPS). In a preliminary step, the QLQ-C30 was found to have acceptable reliability (internal consistency and test-retest reliability). Newly-diagnosed patients and those with a KPS of 80-100 had significantly better physical, role and cognitive functioning and global quality of life with less fatigue, visual disorder, motor dysfunction, communication deficit, weakness of both legs and trouble controlling the bladder than did those with recurrent disease and those with a KPS of 50-70. Similarly, those capable of independent activities of daily living, as reported on the BADLI, had higher functioning scores and less fatigue than did those who were not independent. Patients with dysphasia, mental confusion or motor deficit on neurological examination reported significantly lower levels of physical, role, cognitive, emotional and social functioning and global quality of life than did patients not having these difficulties. They also had significantly more symptoms. In patients with deteriorating neurological status between baseline and follow-up, there was a marked decline in cognitive, physical, role, emotional and social functioning and global quality of life and an increase in fatigue. Thus, there are significant differences in HQL between patients with newly-diagnosed and recurrent brain cancer and between patients with differing KPS and BADLI scores. In addition, the HQL scores provide details not provided by the KPS and the BADLI. Deterioration in neurological function is accompanied by significant deterioration in a range of HQL domains and in global quality of life.

MeSH Terms
Adolescent Adult Aphasia/etiology Brain Neoplasms/complications,pathology,physiopathology Confusion/etiology Female Follow-Up Studies Glioma/complications,pathology,physiopathology Health Status Humans Male Neoplasm Recurrence, Local/physiopathology Nervous System Diseases/etiology Psychometrics Psychomotor Performance/physiology Quality of Life Reproducibility of Results Surveys and Questionnaires
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Osoba D
British Columbia Cancer Agency (Vancouver Cancer Centre, Canada.
Aaronson N K
Muller M
Sneeuw K
Hsu M A
Yung W K
Brada M
Newlands E
References (28)
28 references, click to expand
  1. Recording neurological impairment in clinical trials of glioma.
    J Neurooncol. 1994;19(1):37-49 PMID: 7815103
  2. The development of a method for assessing the quality of life of cancer patients.
    Br J Cancer. 1984 Jul;50(1):13-22 PMID: 6743512
  3. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires.
    Qual Life Res. 1996 Feb;5(1):139-50 PMID: 8901377
  4. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group.
    Qual Life Res. 1997 Mar;6(2):103-8 PMID: 9161109
  5. A method for assessing the quality of life of cancer patients: replication of the factor structure.
    Br J Cancer. 1992 Jun;65(6):961-6 PMID: 1616871
  6. Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire.
    J Clin Oncol. 1995 May;13(5):1249-54 PMID: 7738629
  7. Cognitive functioning in long-term survivors of high-grade glioma.
    J Neurosurg. 1994 Feb;80(2):247-53 PMID: 8283263
  8. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation.
    J Clin Oncol. 1984 May;2(5):472-83 PMID: 6374052
  9. Quality of life during chemotherapy for small cell lung cancer. II. A longitudinal study of the EORTC Core Quality of Life Questionnaire and comparison with the Sickness Impact Profile.
    Acta Oncol. 1992;31(1):19-28 PMID: 1316770
  10. Quality of life self-reports from 200 brain tumor patients: comparisons with Karnofsky performance scores.
    J Neurooncol. 1992 Nov;14(3):243-53 PMID: 1460487
  11. The impact of generalized malignant melanoma on quality of life evaluated by the EORTC questionnaire technique.
    Qual Life Res. 1993 Jun;2(3):193-203 PMID: 8401455
  12. Psychometric validation of the EORTC Core Quality of Life Questionnaire, 30-item version and a diagnosis-specific module for head and neck cancer patients.
    Acta Oncol. 1992;31(3):311-21 PMID: 1622651
  13. The Quality of Life Committee of the Clinical Trials Group of the National Cancer Institute of Canada: organization and functions.
    Qual Life Res. 1992 Jun;1(3):211-8 PMID: 1301129
  14. Test for item bias in a quality of life questionnaire.
    J Clin Epidemiol. 1995 Jun;48(6):805-16 PMID: 7769411
  15. The Karnofsky Performance Status Scale re-examined: a cross-validation with the EORTC-C30.
    Qual Life Res. 1994 Dec;3(6):413-24 PMID: 7866359
  16. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
    J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 PMID: 8433390
  17. The use of significant others as proxy raters of the quality of life of patients with brain cancer.
    Med Care. 1997 May;35(5):490-506 PMID: 9140337
  18. Quality-of-life assessment: patient compliance with questionnaire completion.
    J Natl Cancer Inst. 1992 Jul 1;84(13):1023-6 PMID: 1608053
  19. The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy.
    Eur J Cancer. 1995 Dec;31A(13-14):2260-3 PMID: 8652253
  20. Measurement of quality of life in patients: psychometric analyses of the Functional Living Index-Cancer (FLIC).
    Qual Life Res. 1992 Oct;1(5):287-96 PMID: 1299460
  21. CAncer Rehabilitation Evaluation System--short form (CARES-SF). A cancer specific rehabilitation and quality of life instrument.
    Cancer. 1991 Sep 15;68(6):1406-13 PMID: 1873793
  22. Assessment of quality of life in patients treated for low-grade glioma: a preliminary report.
    J Neurol Neurosurg Psychiatry. 1992 May;55(5):372-6 PMID: 1602310
  23. Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses.
    Qual Life Res. 1993 Apr;2(2):129-40 PMID: 8518767
  24. The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors.
    Cancer. 1995 Mar 1;75(5):1151-61 PMID: 7850714
  25. A validation study of the domains of the core EORTC quality of life questionnaire.
    Qual Life Res. 1993 Oct;2(5):319-25 PMID: 8136796
  26. Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group.
    Br J Haematol. 1996 Mar;92 (3):604-13 PMID: 8616024
  27. Health-related quality-of-life studies of the National Cancer Institute of Canada Clinical Trials Group.
    J Natl Cancer Inst Monogr. 1996;(20):107-11 PMID: 8750480
  28. Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer.
    Qual Life Res. 1994 Oct;3(5):353-64 PMID: 7841968
Article Info
Journal
Journal of neuro-oncology
Abbr.
J Neurooncol
ISSN
0167-594X
Published
1997-09-00
Pages
263-78
Language
English
Region
United States
NLM ID
8309335
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com